Therefore, TIM-3 is recognized as a promising target for immunotherapy and monoclonal anti-TIM-3 antibodies are currently under evaluation in several clinical trials for AML and high-risk MDS (myelodysplastic syndrome) in combination with cytotoxic therapies (NCT04266301, NCT04150029, NCT04823624, NCT03946670, NCT04878432, NCT03940352, and NCT03066648). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.